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Purpose: To evaluate the direct anti-cancer effect of a single instillation of epirubicin 
(SIE) after transurethral resection of bladder tumor (TURBT) for non-muscle-invasive 
bladder cancer (NMIBC) by analysis of immediate urine cytology (IUC).
Materials and Methods: We reviewed the records of 158 patients who had IUC after 
TURBT for NMIBC. Fifty-six patients were treated with SIE after TURBT and 102 pa-
tients were not treated with SIE. The direct anti-cancer effect of SIE was compared 
in the two groups according to the result of IUC. The relationship between SIE and IUC 
in NMIBC was analyzed by use of multivariate Cox proportional hazards regression 
models.
Results: The IUC-positive rate was 33.9% in the SIE group and 42.1% in the non-SIE 
group (p=0.005). The IUC-positive rate was lower in the SIE group than in the non-SIE 
group for each factor, including tumor stage, tumor grade, tumor size, tumor multi-
plicity, and preoperative urine cytology. Multivariate Cox proportional hazards re-
gression analysis revealed that SIE was significantly associated with a negative IUC 
result in patients with NMIBC (HR, 0.163) (p＜0.001).
Conclusions: These results indicate the direct anti-cancer effect of SIE in patients who 
undergo TURBT for NMIBC.
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INTRODUCTION
Bladder cancer is the most common urological malignancy 
in Korea [1,2]. Transurethral resection of bladder tumor 
(TURBT) is commonly performed for the diagnosis and ini-
tial therapy of bladder cancer [3]. Although non-muscle-in-
vasive bladder cancer (NMIBC) can be treated with tran-
surethral resection of bladder tumor (TURBT), the high 
frequency of intravesical recurrence is a serious concern. 
It was reported that intravesical recurrence occurred in 50 
to 70% of patients within 5 years after TURBT for NMIBC 
and that the risk of progression to invasive cancer was 5 
to 20% [4]. A common belief is that freely floating tumor 
cells adhere to the bladder mucosa during TURBT, result-
ing in the formation of new tumors that are detected at fol-
low-up. Popeert et al. [5] noted that a single instillation of 
epirubicin (SIE) into the bladder had a significant effect on 
marker lesions with acceptable toxicity. A number of 
randomized studies have shown that a single instillation 
of a cytotoxic drug, mainly epirubicin or mitomycin, de-
creases the number of subsequent recurrences [6-8].
Knowledge is lacking, however, about the direct an-
ti-cancer effect of the single instillation concept. Thus, we 
assessed the direct anti-cancer effect of SIE after TURBT 
for NMIBC by analyzing the results of immediate urine cy-
tology (IUC).Korean J Urol 2012;53:78-81
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TABLE 1. Baseline characteristics of the patients in the SIE group 
and non-SIE group
SIE group Non-SIE group p-value
Stage
    Ta
    T1
Grade 
    Low
    High
Size (cm)
    ＜3 
    ≥3 
Multiplicity
    1
    2-3
    ≥4
PUC
    Positive
    Negative
27
29
25
31
44
12
31
17
8
15
41
48
54
50
52
67
35
40
45
17
36
66
0.081
0.075
0.266
0.156
0.263
SIE, single instillation of epirubicin; PUC, preoperative urine 
cytology.
TABLE 2. Relationships between IUC and SIE for 5 variables
Variable
IUC Group
p-value
Negative (n=96) Positive (n=62)
Stage (Ta/T1)
Grade (low/high)
Size (＜3 cm/≥3 cm)
Multiplicity 
(1/2-3/≥4)
SIE/Non-SIE
PUC (+/-)
55/41
49/47
73/23
52/33/11
37/59
11/85
20/42
26/36
38/24
19/29/14
19/43
40/22
   0.042
＜0.001
   0.033
   0.001
＜0.001
   0.018
IUC, immediate urine cytology; SIE, single instillation of epi-
rubicin; PUC, preoperative urine cytology.
MATERIALS AND METHODS
We reviewed the records of 158 patients who had IUC after 
TURBT for NMIBC from October 2003 to January 2011, ex-
cluding patients who had muscle-invasive bladder cancer, 
metastatic bladder cancer, or combined urinary upper 
tract tumor and carcinoma in situ (CIS) confirmed by per-
manent biopsy. Among 158 patients, 56 patients were 
treated with SIE after TURBT and 102 patients were not 
treated with SIE. Patients received 50 mg epirubicin in 50 
ml saline solution, which was instilled within 6 hours after 
TURBT. The catheter was clamped for 1 hour. Patients also 
received bladder irrigation twice a day during the post-
operative days. The Foley catheter was removed when the 
gross hematuria had resolved after TURBT. Before Foley 
catheter removal, washed urine for IUC was obtained by 
bladder irrigation with 0.9% normal saline solution. IUC 
was evaluated by a pathologist in accordance with the 1999 
World Health Organization (WHO) classification. The cy-
tology was categorized as positive if cancer cells or cells 
with atypical changes suggesting malignancy were found, 
and it was regarded as negative in cases with mild to moder-
ate atypical changes.
Tumors were staged according to the 2002 American 
Joint Committee on Cancer staging system. Tumors were 
graded according to the 2004 WHO/International Society of 
Urologic Pathology (WHO/ISUP) classification of urothelial 
neoplasia. Tumor size was classified as either less than 3 
cm tumor diameter or 3 cm or larger tumor diameter. 
Tumor multiplicity was classified into 1 and 2-3 lesions and 
more than 3 lesions. 
The direct anti-cancer effect of SIE was compared in the 
two groups according to IUC. Comparison of the patients’ 
baseline characteristics between the SIE group and the 
non-SIE group was performed by chi-square test. Chi-square 
tests were also performed to measure the association be-
tween IUC and SIE with 5 variables, including tumor 
stage, tumor grade, tumor size, tumor multiplicity, and 
preoperative urine cytology. The IUC-positive rate of the 
SIE and non-SIE groups was compared by chi-square tests. 
The relationship between SIE and IUC in NMIBC was 
studied by use of multivariate Cox proportional hazards re-
gression models. Statistical analysis was performed by use 
of SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA), and p＜0.05 
were considered statistically significant.
RESULTS
The median (range) age of the patients was 63 (range, 35 
to 88) years. The median follow-up period was 21 (range, 
3 to 77) months. Table 1 shows the tumor stage, tumor 
grade, tumor size, tumor multiplicity, and preoperative 
urine cytology of the SIE group and the non-SIE group. 
There were no significant differences in tumor stage, tumor 
grade, tumor size, tumor multiplicity, or preoperative 
urine cytology between the two groups. 
In the total patients, 62 patients (39.3%) had a positive 
IUC result and 96 patients (60.7%) had a negative IUC 
result. Table 2  shows the relationship between a positive 
IUC result and SIE for the 5 variables. In the positive IUC 
group, tumor stage was higher than in the negative IUC 
group (p=0.042). Also, tumor grade was higher (p＜0.001) 
and more tumor lesions were present in the positive IUC 
group (p=0.001). Tumor size was larger in the positive IUC 
group and there was a significant difference between the 
two groups (p=0.033). In the positive IUC group, more pre-
operative urine cytology was positive than in the negative 
IUC group, and the difference between groups was sig-
nificant (p=0.018). In the negative IUC group, SIE treat-
ment was greater than in the positive IUC group, and this 
difference was significant (p＜0.001).
The IUC positive rate was 33.9% in the SIE group and 
42.1% in the non-SIE group (p=0.005). In the SIE group, 
the IUC positive rate was lower for each factor, including 
tumor stage, tumor grade, tumor size, tumor multiplicity, 
and preoperative urine cytology (Table 3). Multivariate Korean J Urol 2012;53:78-81
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TABLE 3. Comparison of the IUC positive rate between the two 
groups
Variable SIE group Non-SIE group p-value
Total
Stage
    Ta (n=75)
    T1 (n=83)
Grade 
    Low (n=75)
    High (n=83)
Size (cm)
    ＜3 (n=111)
    ≥3 (n=47)
Multiplicity
    1 (n=71)
    2-3 (n=62)
    ≥4 (n=25)
PUC
    Positive (n=51)
    Negative (n=107)
19/56 (33.9)
  6/20 (30.0)
13/36 (36.1)
  5/20 (25.0)
14/36 (38.9)
  5/30 (16.7)
14/26 (53.8)
  5/30 (16.7)
  4/11 (36.4)
10/15 (66.7)
12/26 (46.2)
  7/30 (23.3)
43/102 (42.1)
20/55 (36.4)
23/47 (48.9)
19/55 (34.5)
24/47 (51.1)
30/81 (37.0)
13/21 (61.9)
  9/41 (22.0)
27/51 (52.9)
  7/10 (70.0)
13/25 (52.0)
30/77 (39.0)
0.005
0.004
0.002
0.135
0.224
0.003
0.125
0.665
0.372
0.026
0.031
0.012
Values are presented as no. of patients with positive IUC/total (%).
IUC, immediate urine cytology; SIE, single instillation of epi-
rubicin, PUC; preoperative urine cytology.
TABLE 4. Multivariate analysis of the relationship between IUC 
and SIE for 5 variables
Variable Hazard ratio p-value 95% CI
Stage (Ta/T1)
Grade (low/high)
Size (＜3 cm/≥3 cm)
Multiplicity 
PUC (+/-)
SIE
0.974
1.217
1.453
3.733
1.278
0.163
   0.065
   0.352
   0.035
   0.025
   0.023
＜0.001
0.698-1.736
0.502-2.133
1.037-2.645
  1.185-11.254
0.732-1.683
0.042-0.350
IUC, immediate urine cytology; SIE, single instillation of epi-
rubicin; PUC, preoperative urine cytology.
Cox proportional hazards regression analysis revealed 
that tumor size (HR, 1.453; p=0.035), tumor multiplicity 
(HR, 3.733; p=0.025), and preoperative urine cytology (HR, 
1.278; p=0.023) were significantly associated with IUC in 
the patients with NMIBC (Table 4). Also, SIE was sig-
nificantly associated with IUC in the patients with NMIBC 
(HR, 0.163; p＜0.001) (Table 4). We can therefore recognize 
a direct anti-cancer effect of SIE in the patients who under-
went TURBT for NMIBC.
DISCUSSION
Epirubicin, a derivative of doxorubicin, is an anthracycline 
antibiotic that undergoes minimal trans-urothelial ab-
sorption [9]. It was reported that epirubicin has anti-tumor 
efficacy that decreases the recurrence rate when used an 
intravesical chemotherapeutic agent after TURBT for su-
perficial bladder cancer [10,11]. In a large controlled study 
performed by the European Organization for the Research 
and Treatment of Cancer, Oosterlinck et al. [8] reported 
that a single instillation of 80 mg epirubicin given immedi-
ately (within 6 hours) after TURBT decreased the re-
currence rate by nearly 50% compared with the water-in-
stilled group. Epirubicin is a chemotherapeutic drug that 
has a favorable tolerability profile and has been shown to 
prevent recurrences in patients with low- and inter-
mediate-risk NMIBC [12,13]. Therefore, we used epi-
rubicin as a primary agent. We used a dose of 50 mg epi-
rubicin based on the successful results of Ali-el-Dein et al. 
[10], but better results may be achieved with a dose of 80 
mg epirubicin. We are going to adjust the titration of 
epirubicin.
There are many reports regarding the timing and dura-
tion of instillation therapy, including epirubicin [14,15]. 
Instillation of epirubicin immediately after TURBT for su-
perficial bladder cancer significantly decreased disease re-
currence compared with instillation of water [15]. It was 
reported that one of the mechanisms of intravesical re-
currence after TURBT of bladder cancer is implantation of 
tumor cells in the bladder wall, and instillation immedi-
ately after TURBT seems to be effective in preventing free 
tumor cells from implanting in the bladder wall during or 
after TURBT [16]. However, no research has studied the 
direct effect of SIE. 
The initial diagnosis and follow-up of previous bladder 
cancer are commonly based on urine cytology and cystoscopy. 
The sensitivity value of urinary cytology for detecting blad-
der cancer reported in various series ranges from 16 to 60% 
[17]. Budman et al. [18] reported that urine cytology has 
12.1 to 84.6% sensitivity and 78.0 to 100% specificity [13]. 
The high specificity is the most important feature of cytol-
ogy, because a positive reading regardless of cystoscopic or 
radiographic findings suggests the existence of malig-
nancy in the vast majority of patients [18]. IUC has the 
same pathological property as usual follow-up urine cytol-
ogy, although IUC can predict cancer recurrence immedi-
ately [19]. Also, IUC is an easy and noninvasive examina-
tion method for detecting recurrence of NMIBC.
Several studies have suggested risk tables for recurrence 
and progression of NMIBC, such as number of tumors, tu-
mor size, prior recurrence rate, T category, and presence 
of CIS [20]. However, these cannot sufficiently reflect the 
probability of recurrence. Situations such as tumor im-
plantation after TURBT, invisible tumor during TURBT, 
and incomplete TURBT can be a reason for cancer 
recurrence. In our study, tumor stage, tumor grade, tumor 
size, tumor multiplicity, and preoperative urine cytology 
also had a significant relationship with positive IUC.
There are some reasons for cancer recurrence after 
TURBT. Tumor implantation can be an important reason. 
The concept that tumor cells implant on the altered ur-
othelial surface, such as after endoscopic resection, has 
been demonstrated in animal models [10]. The fact that 
early postoperative chemotherapy reduces the recurrence 
rates strongly suggests that implantation of liberated tu-Korean J Urol 2012;53:78-81
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mor cells is one of the mechanisms responsible for re-
currence [10]. In our study, we were focused on tumor im-
plantation as the reason for recurrence. The IUC positive 
rate was lower in the SIE group. Also, SIE was significantly 
associated with IUC in the patients with NMIBC. This re-
sult means that SIE has an effect of preventing free tumor 
cells from implanting in the bladder wall after TURBT. 
Our analysis is limited in that we were unable to evaluate 
cancer recurrence. In addition, studies with standardized 
protocols for evaluating cancer recurrence after TURBT for 
NMIBC in the SIE group and non-SIE group are needed to 
verify our findings.
CONCLUSIONS
SIE has a role in preventing free tumor cells from implant-
ing in the bladder wall after TURBT. Our study indicates 
the direct anti-cancer effect of SIE in patients who under-
went TURBT for NMIBC. To our knowledge, this is the first 
trial to reveal a direct anti-cancer effect of SIE.
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